Anti-CD18 [H52]

Absolute Antibody

Anti-CD18 [H52]

9

This antibody binds disulfide-bonded loop (C386and C400) in the beta-2 integrin subunit. It is reported that the epitope of H52 is masked in the integrin Mac-1 and p150,95.

This antibody is successfully capable of inhibiting T cell, natural killer cells and complement receptor type 3 functions. Binding specificity of this antibody was confirmed with immunoprecipitation (PMID: 2580022). H52 mAb blocked 8E5-PHA-blast fusion in a dose-dependent manner with complete inhibition observed at concentrations above 3 microg/ml. Cell fusion (syncytium formation) is a major cytopathic effect of infection by human immunodeficiency virus (HIV). To determine the effect of the mAb on syncytium formation the LFA-1 expression of 8E5 cells and PHA-blasts was checked by flow cytometry. This mAb inhibited HIV-induced syncytium formation, however it did not block binding of gp120 to CD4 (PMID: 2543075). This mAb cross reacts with procine LFA-1 and profoundly inhibited mitogenic and allogenic stimulation of porcine T lymphocytes as well as cytotoxic T cell and natural killer (NK) cell function (PMID: 2481234). The expression of H52 epitope on beta-2 subunit isdependent on its interation with different alpha subunits of the leukocyte integrin LFA-1, Mac-1 and p150,95 and presence of calcium ions. The expression of the H52 epitope was examined by immunoprecipitation (PMID: 9808198).

Flow Cytometry, ImmunoPrecipitation, Neutralisation/Blocking

Research Use Only

Monoclonal

H52

ITGB2

integrin subunit beta 2

CD18; cell surface adhesion glycoprotein (LFA-1/CR3/P150,959 beta subunit precursor); complement component 3 receptor 3 and 4 subunit; complement receptor C3 beta-subunit; integrin beta chain, beta 2; integrin beta-2; integrin, beta 2 (complement component 3 receptor 3 and 4 subunit); LAD; LCAMB; leukocyte cell adhesion molecule CD18; leukocyte-associated antigens CD18/11A, CD18/11B, CD18/11C; LFA-1; MAC-1; MF17; MFI7; truncated integrin beta-2

Human

IgG1

Integrin beta-2

This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques.

Canine, Human, Porcine

-20°C,2°C to 8°C

12352203